Atyr Pharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atyr Pharma, Inc. on December 10, 2024. The filing reports corporate governance changes effective immediately on the date of the report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and compensation policy updates rather than financial performance.
Material Changes
- Board Appointment: Eric Benevich was appointed to the Board of Directors as a Class II director, effective December 10, 2024. His term will last until the 2026 annual meeting of stockholders or until a successor is elected.
- Compensation Policy Update: The Board amended and restated the Non-Employee Director Compensation Policy (filed as Exhibit 99.1).
- Director Compensation: Mr. Benevich received an option to purchase 100,000 shares of common stock at the closing price on December 10, 2024. The option vests in equal monthly installments over three years, contingent on continued service.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, or contingencies. No unusual items or financial contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the terms of the Amended Director Compensation Policy in Exhibit 99.1.
- Confirm the vesting schedule and exercise price of the 100,000 share option granted to Eric Benevich.
- Review the Company's most recent 10-K or 10-Q for current financial status, as this 8-K contains no financial data.